Alpha 2.0
Login Register
» Authors » Piotr Domanski

Piotr Domanski

Explore the profile of Piotr Domanski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 4
Followers 0
Related Specialties
Oncology
Biomedical Engineering
General Medicine
Top 10 Co-Authors
Tomasz Demkow
Mateusz Pietak
Jakub Kucharz
Barbara Kruczyk
Bozena Sikora-Kupis
Anna Mydlak
Paulina Dumnicka
Marta Darewicz
Jadwiga Jarosinska
Lukasz Kuncman
Published In
Contemp Oncol (Pozn)
Biomedicines
Medicina (Kaunas)
Affiliations
Soon will be listed here.
Recent Articles
1.
Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review
Domanski P, Pietak M, Staneta S, Fortuniak W, Kruczyk B, Kobiernik A, et al.
Medicina (Kaunas) . 2024 Mar; 60(3). PMID: 38541124
More than 430,000 new cases of renal cell carcinoma (RCC) were reported in 2020. Clear cell RCC, which occurs in 80% of cases, is often associated with mutations in the...
2.
Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective study
Domanski P, Jarosinska J, Kruczyk B, Pietak M, Mydlak A, Demkow T, et al.
Contemp Oncol (Pozn) . 2024 Feb; 27(4):242-248. PMID: 38405212
Introduction: Geriatric patients with metastatic renal cell carcinoma (mRCC) are underrepresented in clinical trials. Evaluation of the efficacy of the treatment and assignation of individuals to proper prognostic groups is...
3.
First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
Sikora-Kupis B, Domanski P, Fortuniak W, Kruczyk B, Staneta S, Pietak M, et al.
Contemp Oncol (Pozn) . 2024 Feb; 27(4):224-229. PMID: 38405211
Introduction: Urothelial carcinoma is the most common type of urinary tract malignancy. Current treatment options, including platinum-based chemotherapy or immunotherapy, present significant challenges, ranging from limited efficacy to severe toxicities....
4.
Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study
Domanski P, Pietak M, Kruczyk B, Jarosinska J, Mydlak A, Demkow T, et al.
Biomedicines . 2024 Feb; 12(2). PMID: 38398014
Cabozantinib, an oral inhibitor targeting MET, AXL, and VEGF receptors, has become a key component of a sequential treatment strategy for clear cell renal cell carcinoma (ccRCC). The purpose of...
5.
Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective study
Domanski P, Jarosinska J, Kruczyk B, Pietak M, Mydlak A, Demkow T, et al.
Contemp Oncol (Pozn) . 2024 Jan; 27(3):190-197. PMID: 38239858
Introduction: Cabozantinib is an oral inhibitor of MET, AXL, and vascular endothelial growth factor receptors. It has an immunomodulatory effect and may influence the tumor's microenvironment and make mutated cells...
6.
Prostate Cancer in Transplant Receivers-A Narrative Review on Oncological Outcomes
Hanusz K, Domanski P, Strojec K, Zapala P, Zapala L, Radziszewski P
Biomedicines . 2023 Nov; 11(11). PMID: 38001942
Prostate cancer (PCa) is a low tumor mutational burden (TMB) cancer with a poor response to immunotherapy. Nonetheless, immunotherapy can be useful, especially in metastatic castration-resistant PCa (mCRPC). Increased cytotoxic...